JP2023504016A5 - - Google Patents
Info
- Publication number
- JP2023504016A5 JP2023504016A5 JP2022530837A JP2022530837A JP2023504016A5 JP 2023504016 A5 JP2023504016 A5 JP 2023504016A5 JP 2022530837 A JP2022530837 A JP 2022530837A JP 2022530837 A JP2022530837 A JP 2022530837A JP 2023504016 A5 JP2023504016 A5 JP 2023504016A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- bcma
- cdr
- polypeptide chain
- chain comprises
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024185441A JP7847630B2 (ja) | 2019-11-26 | 2024-10-21 | Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質 |
| JP2026063021A JP2026108862A (ja) | 2019-11-26 | 2026-04-07 | Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019120991 | 2019-11-26 | ||
| CNPCT/CN2019/120991 | 2019-11-26 | ||
| CN2020111796 | 2020-08-27 | ||
| CNPCT/CN2020/111796 | 2020-08-27 | ||
| PCT/CN2020/131767 WO2021104371A1 (en) | 2019-11-26 | 2020-11-26 | Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185441A Division JP7847630B2 (ja) | 2019-11-26 | 2024-10-21 | Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023504016A JP2023504016A (ja) | 2023-02-01 |
| JP2023504016A5 true JP2023504016A5 (cg-RX-API-DMAC7.html) | 2023-12-01 |
| JP7773466B2 JP7773466B2 (ja) | 2025-11-19 |
Family
ID=76130007
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022530837A Active JP7773466B2 (ja) | 2019-11-26 | 2020-11-26 | Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質 |
| JP2024185441A Active JP7847630B2 (ja) | 2019-11-26 | 2024-10-21 | Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質 |
| JP2026063021A Pending JP2026108862A (ja) | 2019-11-26 | 2026-04-07 | Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024185441A Active JP7847630B2 (ja) | 2019-11-26 | 2024-10-21 | Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質 |
| JP2026063021A Pending JP2026108862A (ja) | 2019-11-26 | 2026-04-07 | Cd3およびbcmaに対する抗体およびそれらから作製した二重特異性結合タンパク質 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230002489A1 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4065164A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP7773466B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR20240162588A (cg-RX-API-DMAC7.html) |
| CN (1) | CN114728065A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020390288A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3160163A1 (cg-RX-API-DMAC7.html) |
| IL (2) | IL293138A (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022006230A (cg-RX-API-DMAC7.html) |
| TW (1) | TWI774137B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021104371A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2014374055B2 (en) * | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| IL300760A (en) * | 2020-08-24 | 2023-04-01 | Epimab Biotherapeutics Hk Ltd | Anti-ROR1 antibodies and related bispecific binding proteins |
| US20250051443A1 (en) * | 2021-10-07 | 2025-02-13 | National Research Council Of Canada | Anti-cd3 monoclonal antibodies and therapeutic constructs |
| CN116375868A (zh) * | 2021-12-31 | 2023-07-04 | 康源博创生物科技(北京)有限公司 | 一种抗cd3的人源化抗体及其在制备双特异性抗体中的应用 |
| CN117003871A (zh) | 2022-04-28 | 2023-11-07 | 北京天广实生物技术股份有限公司 | 结合bcma和cd3的抗体及其用途 |
| WO2024012513A1 (en) * | 2022-07-13 | 2024-01-18 | Hansoh Bio Llc | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof |
| WO2024074145A1 (zh) * | 2022-10-08 | 2024-04-11 | 盛禾(中国)生物制药有限公司 | 一种结合baffr和cd3的双特异性抗体及其应用 |
| CN120418284A (zh) * | 2022-12-19 | 2025-08-01 | 和铂医药(上海)有限责任公司 | “κ/λ” Fab-Fab串联多特异性结合蛋白及其制备和应用 |
| EP4719352A1 (en) | 2023-05-31 | 2026-04-08 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| CN117024596B (zh) * | 2023-08-18 | 2024-02-27 | 镜像绮点(上海)细胞技术有限公司 | 肿瘤原代细胞特异性标记与活体成像 |
| US20250127728A1 (en) | 2023-10-05 | 2025-04-24 | Capstan Therapeutics, Inc. | Constrained Ionizable Cationic Lipids and Lipid Nanoparticles |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025131077A1 (zh) * | 2023-12-21 | 2025-06-26 | 上海君实生物医药科技股份有限公司 | 抗cd3多特异性抗体及用途 |
| WO2025168059A1 (zh) * | 2024-02-08 | 2025-08-14 | 天劢源和生物医药(上海)有限公司 | 靶向bcma、cd19和cd3的多特异性抗原结合蛋白及其应用 |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・2・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| FI903489A7 (fi) | 1988-11-11 | 1990-07-10 | Medical Res Council | Yhden osan sisältävät ligandit, näitä ligandeja sisältävät reseptorit, menetelmiä niiden valmistamiseksi sekä ligandien ja reseptorien käytt ö |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| US8236308B2 (en) | 2005-10-11 | 2012-08-07 | Micromet Ag | Composition comprising cross-species-specific antibodies and uses thereof |
| EP2714737A1 (en) | 2011-05-27 | 2014-04-09 | Glaxo Group Limited | Bcma (cd269/tnfrsf17) -binding proteins |
| JP6636803B2 (ja) | 2013-02-05 | 2020-01-29 | エンクマフ エスアーエールエル | Bcmaに対する抗体の選択のための方法 |
| HUE050159T2 (hu) * | 2013-12-17 | 2020-11-30 | Genentech Inc | Anti-CD3 antitestek és alkalmazási eljárások |
| AU2014374055B2 (en) * | 2013-12-30 | 2018-11-08 | Epimab Biotherapeutics Inc. | Fabs-in-tandem immunoglobulin and uses thereof |
| EP2982692A1 (en) | 2014-08-04 | 2016-02-10 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| EP3023437A1 (en) * | 2014-11-20 | 2016-05-25 | EngMab AG | Bispecific antibodies against CD3epsilon and BCMA |
| HUE057285T2 (hu) * | 2015-04-13 | 2022-04-28 | Pfizer | Terápiás ellenanyagok és alkalmazásaik |
| EP3310811B1 (en) * | 2015-06-16 | 2021-06-16 | Genentech, Inc. | Anti-cd3 antibodies and methods of use |
| JP7014724B2 (ja) * | 2016-02-06 | 2022-02-01 | エピムアブ バイオセラピューティクス インコーポレイテッド | タンデム型Fab免疫グロブリンおよびその使用 |
| IL299221A (en) * | 2016-06-21 | 2023-02-01 | Teneobio Inc | Cd3 binding antibodies |
| CA3032430A1 (en) * | 2016-08-16 | 2018-02-22 | Epimab Biotherapeutics, Inc. | Monovalent asymmetric tandem fab bispecific antibodies |
| WO2018224441A1 (en) * | 2017-06-05 | 2018-12-13 | Numab Innovation Ag | Novel anti-cd3 antibodies |
| CN109535257B (zh) * | 2017-09-22 | 2021-05-28 | 同润生物医药(上海)有限公司 | 新型双特异性cd3/cd19多肽复合物 |
| EP3732199A1 (en) * | 2017-12-27 | 2020-11-04 | TeneoBio, Inc. | Cd3-delta/epsilon heterodimer specific antibodies |
| CN112074541A (zh) * | 2018-05-03 | 2020-12-11 | 上海岸迈生物科技有限公司 | Pd-1和lag-3的高亲和力抗体以及由其制备的双特异性结合蛋白 |
| WO2019220368A1 (en) * | 2018-05-16 | 2019-11-21 | Janssen Biotech, Inc. | Bcma/cd3 and gprdc5d/cd3 bispecific antibodies for use in cancer therapy |
-
2020
- 2020-11-26 TW TW109141514A patent/TWI774137B/zh active
- 2020-11-26 MX MX2022006230A patent/MX2022006230A/es unknown
- 2020-11-26 EP EP20892443.1A patent/EP4065164A4/en active Pending
- 2020-11-26 JP JP2022530837A patent/JP7773466B2/ja active Active
- 2020-11-26 IL IL293138A patent/IL293138A/en unknown
- 2020-11-26 KR KR1020247036665A patent/KR20240162588A/ko active Pending
- 2020-11-26 IL IL316618A patent/IL316618A/en unknown
- 2020-11-26 US US17/776,167 patent/US20230002489A1/en not_active Abandoned
- 2020-11-26 CA CA3160163A patent/CA3160163A1/en active Pending
- 2020-11-26 CN CN202080081975.5A patent/CN114728065A/zh active Pending
- 2020-11-26 EP EP24211210.0A patent/EP4483895A3/en active Pending
- 2020-11-26 AU AU2020390288A patent/AU2020390288A1/en active Pending
- 2020-11-26 KR KR1020227021084A patent/KR20220104783A/ko active Pending
- 2020-11-26 WO PCT/CN2020/131767 patent/WO2021104371A1/en not_active Ceased
-
2022
- 2022-05-23 MX MX2024013229A patent/MX2024013229A/es unknown
-
2024
- 2024-10-21 JP JP2024185441A patent/JP7847630B2/ja active Active
- 2024-12-12 AU AU2024278367A patent/AU2024278367A1/en active Pending
-
2026
- 2026-04-07 JP JP2026063021A patent/JP2026108862A/ja active Pending